Artesunate

A study in Uganda found that some children with severe malaria show partial resistance to artemisinin, a key antimalarial drug.

• Ionis Pharmaceuticals reports strong progress with WAINUA launch for ATTRv-PN, generating $5 million in royalties for Q3 2024, and securing approvals in the UK and a positive CHMP opinion in Europe. • The company is advancing olezarsen for FCS, with a PDUFA date set for December 19, 2024, and donidalorsen for HAE, with a PDUFA date of August 21, 2025, positioning them for potential launches. • Positive Phase 2/3 DEVOTE study data for higher dose nusinersen in SMA was presented, with global regulatory applications planned, alongside QALSODY's marketing approval in China for SOD1-ALS. • Ionis reaffirms its 2024 financial guidance, increasing cash guidance to $2.2 billion, reflecting proceeds from an equity offering to support pipeline advancements and commercial preparations.

• Ionis Pharmaceuticals reports positive progress with WAINUA, achieving commercial success and regulatory approvals for ATTRv-PN treatment. • Olezarsen's NDA for FCS is under FDA Priority Review with a PDUFA date of December 19, 2024, potentially addressing an unmet need. • Donidalorsen's NDA for HAE has been accepted by the FDA, with a PDUFA date of August 21, 2025, positioning it as a novel prophylactic treatment. • The company is advancing multiple Phase 3 programs, including olezarsen for sHTG and ION582 for Angelman syndrome, with key data expected in the coming years.